Viridian Therapeutics, Inc.
VRDN-008
Countdown
177days
Phase 1 readout Β· ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for VRDN-008 in its lead indication are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
Β· SEC 8-K
verified 15h ago
βdata expected in 2H 2026β